A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.
source https://www.sciencedaily.com/releases/2021/03/210321215440.htm
Monday, 22 March 2021
Related Posts
Correlated electrons ‘tango’ in a perovskite oxide at the extreme quantum limitScientists have found a rare quantum material in which electrons move … Read More
Strikingly simple means of diagnosing ecosystem health uncoveredScientists say the health of a terrestrial ecosystem can be largely de… Read More
Strict lineage tracing crucial to nerve cell regeneration researchStem cell scientists find that stringent lineage tracing is crucial fo… Read More
Exoskeleton research demonstrates the importance of trainingNew research shows that the benefits people could reap from exoskeleto… Read More
Clover growth in Mars-like soils boosted by bacterial symbiosisClover plants grown in Mars-like soils experience significantly more g… Read More
Team rewires a behavioral circuit in the worm using hydra partsNew research highlights the development of HySyn, a system designed to… Read More
0 comments: